MARC details
| 000 -LEADER |
|---|
| fixed length control field |
04651cam a22004937a 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
17591741 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
EG-NcFUE |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20200930112454.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
130115s2012 enka b 001 0 eng |
| 010 ## - LIBRARY OF CONGRESS CONTROL NUMBER |
|---|
| LC control number |
2012472658 |
| 016 7# - NATIONAL BIBLIOGRAPHIC AGENCY CONTROL NUMBER |
|---|
| Record control number |
101580436 |
| Source |
DNLM |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9781848166288 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
1848166281 |
| 035 ## - SYSTEM CONTROL NUMBER |
|---|
| System control number |
(OCoLC)ocn776670289 |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
NLM |
| Language of cataloging |
eng |
| Transcribing agency |
NLM |
| Modifying agency |
CAI |
| -- |
CDX |
| -- |
YDXCP |
| -- |
E7B |
| -- |
BTCTA |
| -- |
BWX |
| -- |
DLC |
| 042 ## - AUTHENTICATION CODE |
|---|
| Authentication code |
nlmcopyc |
| -- |
lccopycat |
| 050 00 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
RS201.A56 |
| Item number |
A58 2012 |
| 060 00 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER |
|---|
| Classification number |
2012 C-123 |
| 060 10 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER |
|---|
| Classification number |
QW 575 |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
615.37 |
| Edition number |
22 |
| Item number |
A |
| 245 00 - TITLE STATEMENT |
|---|
| Title |
Antibody drug discovery / |
| Statement of responsibility, etc |
Clive R. Wood, editor. |
| 264 #1 - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
|---|
| Place of publication, distribution, etc |
London : |
| Name of publisher, distributor, etc |
Imperial College Press, |
| Date of publication, distribution, etc |
[2012]. |
| 264 #4 - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
|---|
| Date of publication, distribution, etc |
©2012 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
xv, 473 pages : |
| Other physical details |
illustrations (some color) ; |
| Dimensions |
24 cm |
| 336 ## - CONTENT TYPE |
|---|
| Source |
rdacontent |
| Content type term |
text |
| 337 ## - MEDIA TYPE |
|---|
| Source |
rdamedia |
| Media type term |
unmediated |
| 338 ## - CARRIER TYPE |
|---|
| Source |
rdacarrier |
| Carrier type term |
volume |
| 490 1# - SERIES STATEMENT |
|---|
| Series statement |
Molecular medicine and medicinal chemistry ; |
| Volume number/sequential designation |
v. 4 |
| 500 ## - GENERAL NOTE |
|---|
| General note |
pharmacy bookfair2016 |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc |
Includes bibliographical references and index. |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Contributors -- Foreword John McCafferty -- Preface Clive R.Wood -- Chapter 1 Humanization of Antibodies Olivier Léger and José W. Saldanha -- 1.1 Introduction -- 1.1.1 First step: chimerization -- 1.2 CDR Grafting: Standard Technology -- 1.2.1 Choice of CDR region to graft -- 1.2.2 Choice of human framework acceptor regions -- 1.2.2.1 Fixed frameworks -- 1.2.2.2 Best fit -- 1.2.2.3 Consensus -- 1.2.2.4 Germline -- 1.2.3 Backmutations -- 1.3 Affinity versus Stability -- 1.4 Alternative Approaches -- 1.4.1 Veneering or resurfacing -- 1.4.2 Grafting of abbreviated CDRs containing specificity-determining residues 1.4.3 Superhumanization1.4.4 Human string content optimization -- 1.4.5 Framework shuffling and human framework adaptation -- 1.4.6 Combinatorial library approaches -- 1.4.6.1 Guided selection -- 1.4.6.2 Framework libraries -- 1.4.7 HumaneeringTM technology -- 1.5 Concluding Remarks -- References -- Chapter 2 Selection and Screening of Antibody Phage Display Libraries David R. Buckler, Darren Schofield, Daniel J. Sexton, David Lowe and Tristan J. Vaughan -- 2.1 Introduction -- 2.2 Antibody Gene Rearrangement and Variable Region Sequence Diversity 2.2.1 Antibody architecture and germline gene segment recombination2.2.2 Variable region sequence diversity and structure guiding library design -- 2.2.3 Amplification of variable region sequence repertoires -- 2.2.4 Antibody sequence databases -- 2.3 Antibody Display Libraries in Ff Bacteriophage -- 2.3.1 Phage biology and early use as a display system -- 2.3.2 Variation of display format and control of display level -- 2.3.2.1 Coat protein display position -- 2.3.2.2 Display format, scFv vs. Fab -- 2.3.2.3 Signal peptide and vector design -- 2.3.2.4 Control of functional display level and valency 2.3.2.5 Maximizing library size2.3.2.6 Assessment of diversity -- 2.3.3 Representative large non-immune libraries -- 2.4 Library Selection -- 2.4.1 Antigen immobilization -- 2.4.2 Overview of phage display selection -- 2.4.3 Advantages and successes of phage display -- 2.4.3.1 Species cross-reactivity -- 2.4.3.2 Homolog binders -- 2.4.3.3 Rare epitopes -- 2.4.3.4 Exquisite specificity -- 2.4.3.5 Cell surface antigens -- 2.4.3.6 Toxins -- 2.4.3.7 High-throughput generation of reagents for proteomics -- 2.4.4 Advances in selection technology -- 2.5 Library Screening -- 2.5.1 Primary screening methods 2.5.2 Secondary screening methods2.5.3 High-throughput antibody purification -- 2.6 Future Applications of Antibody Phage Display -- 2.6.1 Antibody phage display in the proteomics arena -- 2.6.2 Quality protein reagents -- 2.6.3 Affinity maturation of antibody outputs -- 2.6.4 Antibody format and production -- 2.7 Conclusions -- References -- Chapter 3 Affinity Maturation Approaches for Antibody Lead Optimization David Lowe, Trevor Wilkinson and Tristan J. Vaughan -- 3.1 Introduction -- 3.2 Measuring the Affinity of Antibody-Antigen Complexes -- 3.2.1 Improving antibody affinity and potency |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Antibody-drug conjugates. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Drug development. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Immunoglobulins. |
| 650 12 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Antibodies. |
| 650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Drug Discovery. |
| 650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Immunoglobulins. |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Wood, Clive. |
| Relator term |
author. |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE |
|---|
| Uniform title |
Molecular medicine and medicinal chemistry ; |
| Volume number/sequential designation |
v. 4. |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| Materials specified |
Abstract |
| Uniform Resource Identifier |
<a href="http://repository.fue.edu.eg/xmlui/handle/123456789/1826">http://repository.fue.edu.eg/xmlui/handle/123456789/1826</a> |
| 906 ## - LOCAL DATA ELEMENT F, LDF (RLIN) |
|---|
| a |
7 |
| b |
cbc |
| c |
copycat |
| d |
2 |
| e |
ncip |
| f |
20 |
| g |
y-gencatlg |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Books |